{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:51Z","timestamp":1786986951732,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clbc.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T13:48:53Z","timestamp":1520862533000},"page":"e587-e594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Tom\u00e1s","family":"Reinert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Nogueira-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola Procacci","family":"Kestelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ashton-Prolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Silveira","family":"Graudenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.03.006_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1006\/gyno.1994.1333","article-title":"National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up","volume":"55","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib4","first-page":"1","article-title":"3rd ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)","volume":"0","author":"Cardoso","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.AOG.0000154162.51442.14","article-title":"Ovarian malignancy in breast cancer patients with an adnexal mass","volume":"105","author":"Simpikins","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2018.03.006_bib6","first-page":"449","article-title":"Ovarian disease in women with breast cancer","volume":"84","author":"Curtin","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2018.03.006_bib7","doi-asserted-by":"crossref","first-page":"612817","DOI":"10.1155\/2011\/612817","article-title":"Pathways of metastases from primary organs to the ovaries","volume":"2011","author":"Yamanishi","year":"2011","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.clbc.2018.03.006_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1297-9589(01)00131-X","article-title":"[Incidence, diagnosis and prognosis of ovarian metastasis in breast cancer]","volume":"29","author":"Perrotin","year":"2001","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.clbc.2018.03.006_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3346\/jkms.2009.24.1.114","article-title":"Clinical characteristics of metastastic tumors to the ovaries","volume":"24","author":"Lee","year":"2009","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.clbc.2018.03.006_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2005.05.028","article-title":"The role of cytoreductive surgery in nongenital cancer metastatic to the ovaries","volume":"98","author":"Ayhan","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2005.09.046","article-title":"Comparison of secondary and primary ovarian malignancies reveals differences in their pre and perioperative characteristics","volume":"101","author":"Antila","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jgyn.2009.02.003","article-title":"[Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery]","volume":"38","author":"Dubois","year":"2009","journal-title":"J\u00a0Gynecol Obstete Biol Reprod (Paris)"},{"key":"10.1016\/j.clbc.2018.03.006_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2006.11.005","article-title":"Non-genital tract metastasis to the ovaries presented as ovarian tumors in Sweden: occurrence, origin and survival compared to ovarian cancer","volume":"105","author":"Skirnisdottir","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib14","first-page":"2339","article-title":"Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results","volume":"26","author":"Tserkezoglou","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2018.03.006_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cncr.24807","article-title":"Ovarian metastasis from breast cancer","volume":"116","author":"Bigorie","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.03.006_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0090-8258(03)00275-0","article-title":"Breast cancer metastatic to the abdomen and pelvis: role of surgical resection","volume":"90","author":"Eitan","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib17","first-page":"1043","article-title":"Cancer of the ovary after cancer of the breast. 45 cases","volume":"20","author":"Le Thai","year":"1991","journal-title":"Gynecol Obstet Biol Reprod (Paris)"},{"key":"10.1016\/j.clbc.2018.03.006_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/uog.10120","article-title":"Preoperative diagnosis of metastatic ovarian cancer is related to origin of primary tumor","volume":"39","author":"Guerriero","year":"2012","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.clbc.2018.03.006_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1148\/radiology.219.1.r01ap28213","article-title":"Primary versus secondary ovarian malignancy: imaging findings of adnexal mass in the Radiology Diagnostic Oncology Group Study","volume":"219","author":"Brown","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.clbc.2018.03.006_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0090-8258(03)00414-1","article-title":"Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and doppler flow sonography","volume":"91","author":"Ueland","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.anndiagpath.2013.06.003","article-title":"Diagnostic spectrum of ovarian masses in women with breast cancer; magnetic resonance imaging: histopathology correlation","volume":"17","author":"Abd El hafez","year":"2013","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2003.10.026","article-title":"Role of laparoscopy in the evaluation of the adnexa in patients with stage IV breast cancer","volume":"92","author":"Quan","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/gyno.1997.4720","article-title":"Metastatic breast carcinoma to the abdomen and pelvis","volume":"66","author":"Abu-Rustum","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1758834015608993","article-title":"Optimal management of hormone receptor positive metastatic breast cancer in 2016","volume":"7","author":"Reinert","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib25","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor\u2013positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib26","first-page":"183","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2018.03.006_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1148\/radiology.216.1.r00jl15242","article-title":"Adnexal masses in women with breast cancer: US findings with clinical and histopathologic correlation","volume":"216","author":"Hann","year":"2000","journal-title":"Radiology"},{"key":"10.1016\/j.clbc.2018.03.006_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ygyno.2004.06.031","article-title":"Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers","volume":"94","author":"Olawaiye","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01807033","article-title":"Age at diagnosis and multiple primary cancers of the breast and ovary","volume":"41","author":"Suris-Swartz","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.03.006_bib30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1023\/A:1008424527668","article-title":"The accuracy of staging: and important prognostic determinator in stage I ovarian carcinoma","volume":"9","author":"Zanetta","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib31","first-page":"505","article-title":"The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women","volume":"60","author":"Abeliovich","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clbc.2018.03.006_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/gyno.2000.5895","article-title":"Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status","volume":"79","author":"Fishman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(02)11023-3","article-title":"Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study","volume":"360","author":"Bergfeldt","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1016\/j.clbc.2018.03.006_bib34","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib35","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2016.02.014","article-title":"Ovarian cancer: status of homologous recombination pathway as a predictor of drug response","volume":"101","author":"De Picciotto","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2018.03.006_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2008.12.015","article-title":"BRCA1 and implications for response to chemotherapy in ovarian cancer","volume":"113","author":"Quinn","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintanance in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199704173361602","article-title":"Contribution of BRCA1 mutations to ovarian cancer","volume":"336","author":"Stratton","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib40","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/gyno.2001.6430","article-title":"BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study","volume":"83","author":"Smith","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2018.03.006_bib42","doi-asserted-by":"crossref","first-page":"97657","DOI":"10.18632\/oncotarget.18280","article-title":"BRCA mutations in the manifestation and treatment of ovarian cancer","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2018.03.006_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","article-title":"PARP inhibitors in ovarian cancer: evidence, experience and clinical potential","volume":"9","author":"Evans","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib45","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2018.03.006_bib46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib47","doi-asserted-by":"crossref","first-page":"341723","DOI":"10.1155\/2015\/341723","article-title":"Hereditary ovarian cancer: not only BRCA 1 and 2 genes","volume":"2015","author":"Toss","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clbc.2018.03.006_bib48","first-page":"815","article-title":"Diagnosis and management of adnexal masses","volume":"80","author":"Givens","year":"2009","journal-title":"Am Fam Physician"},{"issue":"10 Suppl","key":"10.1016\/j.clbc.2018.03.006_bib49","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/cncr.11345","article-title":"Pathology and classification of ovarian tumors","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.03.006_bib50","series-title":"Management of adnexal masses","author":"American College of Obstetricians and Gynecologists","year":"2007"},{"key":"10.1016\/j.clbc.2018.03.006_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clbc.2018.03.006_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2008.05.006","article-title":"The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial","volume":"110","author":"Johnson","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib53","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.12659\/MSM.896563","article-title":"Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis","volume":"22","author":"Fu","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clbc.2018.03.006_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3892\/mco.2014.419","article-title":"Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer","volume":"3","author":"Geng","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib55","article-title":"Clinical use and optimal cutoff value of CA15-3 in evaluation of adnexal mass: retrospective cohort study and review of the literature","author":"Sagi-Dain","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.006_bib56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2012.11.022","article-title":"Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay","volume":"128","author":"Bristow","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.clbc.2018.03.006_bib57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2018.03.006_bib58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.rcl.2006.10.016","article-title":"Practical approach to the adnexal mass","volume":"44","author":"Patel","year":"2006","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.clbc.2018.03.006_bib59","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/uog.5365","article-title":"Simple ultrasound-based rules for the diagnosis of ovarian cancer","volume":"31","author":"Timmerman","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.clbc.2018.03.006_bib60","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1148\/rg.265045206","article-title":"Developing an MR imaging strategy for diagnosis of ovarian masses","volume":"26","author":"Imaoka","year":"2006","journal-title":"Radiographics"},{"key":"10.1016\/j.clbc.2018.03.006_bib61","first-page":"412","article-title":"Metastatic tumors of the ovary: a clinico-pathological study","volume":"46","author":"Powary","year":"2003","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.clbc.2018.03.006_bib62","first-page":"454","article-title":"[Kr\u00fckenberg tumors of breast origin. 10 cases]","volume":"26","author":"Le Bou\u00ebdec","year":"1997","journal-title":"Presse Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib63","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.5858\/2006-130-1725-AILAKT","article-title":"An in-depth look at Krukenberg tumor: an overview","volume":"130","author":"Al-Agha","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.pas.0000190787.85024.cb","article-title":"Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations","volume":"30","author":"Kyokawa","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib65","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/01.pas.0000176429.88702.36","article-title":"Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary","volume":"29","author":"Tornos","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib66","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/PAS.0b013e31816d71ad","article-title":"Expression of PAX8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas","volume":"32","author":"Nonaka","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0046-8177(89)90137-8","article-title":"Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin","volume":"20","author":"Wick","year":"1989","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcp\/100.1.27","article-title":"Adenocarcinoma in the lung in patients with breast cancer: a prospective analysis of the discriminatory value of immunohistology","volume":"100","author":"Raab","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib69","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0046-8177(91)90084-3","article-title":"Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary","volume":"22","author":"Monteagudo","year":"1991","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib70","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/PGP.0000000000000155","article-title":"Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases","volume":"34","author":"Espinosa","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5858\/arpa.2015-0173-CP","article-title":"Practical applications of immunohistochemistry: carcinomas of unkown primary site","volume":"140","author":"Kandalaft","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clbc.2018.03.006_bib72","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.humpath.2012.11.003","article-title":"GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib73","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin staining in tumor diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2018.03.006_bib74","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/PAS.0b013e3181962dcd","article-title":"Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma","volume":"33","author":"Lotan","year":"2009","journal-title":"Am J Surg Pathol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918300260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918300260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:57Z","timestamp":1761513537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918300260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1526820918300260"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.03.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}